Victory Capital Management
LXRX icon

Victory Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Victory Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.4K Buy
22,679
+1,488
+7% +$2.16K ﹤0.01% 2342
2025
Q4 		$24.4K Buy
21,191
+168
+0.8% +$231 ﹤0.01% 2375
2025
Q3 		$28.4K Sell
21,023
-92
-0.4% -$104 ﹤0.01% 2380
2025
Q2 		$20K Sell
21,115
-518
-2% -$336 ﹤0.01% 2443
2025
Q1 		$9.97K Buy
21,633
+774
+4% +$488 ﹤0.01% 2454
2024
Q4 		$15.4K Sell
20,859
-23,448
-53% -$28.3K ﹤0.01% 2456
2024
Q3 		$69.6K Sell
44,307
-1,034
-2% -$1.84K ﹤0.01% 2359
2024
Q2 		$76.2K Buy
45,341
+13,972
+45% +$25.1K ﹤0.01% 2329
2024
Q1 		$75.3K Sell
31,369
-818
-3% -$1.76K ﹤0.01% 2332
2023
Q4 		$49.2K Buy
32,187
+5,813
+22% +$6.91K ﹤0.01% 2437
2023
Q3 		$28.7K Buy
26,374
+6,123
+30% +$10.7K ﹤0.01% 2425
2023
Q2 		$46.4K Sell
20,251
-472
-2% -$1.25K ﹤0.01% 2395
2023
Q1 		$50.4K Buy
20,723
+300
+1% +$687 ﹤0.01% 2443
2022
Q4 		$39K Sell
20,423
-10
-0% -$21 ﹤0.01% 2472
2022
Q3 		$49K Buy
20,433
+8,873
+77% +$24.6K ﹤0.01% 2569
2022
Q2 		$22K Sell
11,560
-23
-0.2% -$44 ﹤0.01% 2607
2022
Q1 		$21K Sell
11,583
-16,368
-59% -$45.4K ﹤0.01% 2638
2021
Q4 		$110K Buy
27,951
+6,986
+33% +$33.9K ﹤0.01% 2560
2021
Q3 		$101K Buy
20,965
+10,272
+96% +$42.2K ﹤0.01% 2616
2021
Q2 		$49K Buy
10,693
+578
+6% +$2.78K ﹤0.01% 2664
2021
Q1 		$59K Sell
10,115
-2,211
-18% -$15.3K ﹤0.01% 2656
2020
Q4 		$42K Buy
+12,326
New +$23.5K ﹤0.01% 2469
2020
Q2 		– Sell
-107,936
Closed -$210K – 2935
2020
Q1 		$210K Buy
107,936
+57,731
+115% +$172K ﹤0.01% 2318
2019
Q4 		$208K Sell
50,205
-6,314
-11% -$24.3K ﹤0.01% 2302
2019
Q3 		$170K Buy
56,519
+55,014
+3,655% +$170K ﹤0.01% 2269
2019
Q2 		$9K Hold
1,505
– – ﹤0.01% 1812
2019
Q1 		$8K Hold
1,505
– – ﹤0.01% 1767
2018
Q4 		$10K Sell
1,505
-287
-16% -$2.33K ﹤0.01% 1765
2018
Q3 		$19K Sell
1,792
-80,015
-98% -$917K ﹤0.01% 1759
2018
Q2 		$982K Sell
81,807
-4,520
-5% -$46.2K ﹤0.01% 1262
2018
Q1 		$739K Buy
86,327
+84,770
+5,444% +$784K ﹤0.01% 1295
2017
Q4 		$15K Hold
1,557
– – ﹤0.01% 1797
2017
Q3 		$19K Hold
1,557
– – ﹤0.01% 1778
2017
Q2 		$26K Buy
1,557
+27
+2% +$418 ﹤0.01% 1762
2017
Q1 		$22K Hold
1,530
– – ﹤0.01% 1771
2016
Q4 		$21K Buy
1,530
+86
+6% +$1.38K ﹤0.01% 1757
2016
Q3 		$26K Buy
+1,444
New +$23.2K ﹤0.01% 1738

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Victory Capital Management's LXRX Position: Q1 2026 in Review

Victory Capital Management increased its Lexicon Pharmaceuticals (LXRX) stake by 7% in Q1 2026, buying an estimated $2.16K and bringing the position to 22,679 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2342.

Victory Capital Management first reported a position in LXRX in Q3 2016 and has held it in 37 quarters since. The position peaked at $982K in Q2 2018. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Victory Capital Management held 22,679 shares of Lexicon Pharmaceuticals worth $35.4K as of Q1 2026.
  • Victory Capital Management bought 1,488 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $2.16K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2342 holding.
  • Victory Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2016 and has held it in 37 quarters since.
  • Victory Capital Management's Lexicon Pharmaceuticals position peaked at $982K in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.